Ozmosi | AZD-1043 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

AZD-1043

Alternative Names: AZD-1043, AZD 1043, AZD1043
Clinical Status: Active
Latest Update: 2026-04-13
Latest Update Note: Clinical Trial Update

Product Description

ActRII mAb under development by AstraZeneca for obesity. (Sourced from: https://www.astrazeneca.com/our-therapy-areas/pipeline.html)

Mechanisms of Action: ActRII Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-1043

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Obesity

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT07511205

 D9740C00001

P1

Recruiting

Obesity

2027-03-15

50%

2026-04-14

Primary Completion Date|Primary Endpoints

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions